Cover Image
市場調查報告書

酪胺酸蛋白激酶JAK2:開發中產品分析

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 367827
出版日期 內容資訊 英文 135 Pages
訂單完成後即時交付
價格
Back to Top
酪胺酸蛋白激酶JAK2:開發中產品分析 Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Pipeline Review, H2 2017
出版日期: 2017年11月14日 內容資訊: 英文 135 Pages
簡介

本報告提供以酪胺酸蛋白激酶JAK2為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

酪胺酸蛋白激酶JAK2 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥開發企業

  • Aerie Pharmaceuticals, Inc.
  • Aptose Biosciences Inc.
  • Astex Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • Bristol-Myers Squibb Company
  • Celon Pharma Sp. z o.o.
  • Concert Pharmaceuticals, Inc.
  • CTI BioPharma Corp.
  • 第一三共
  • Eli Lilly and Company
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • Merck & Co., Inc.
  • Nerviano Medical Sciences S.r.l.
  • 日本新藥
  • Novartis AG
  • SOM Innovation Biotech SL
  • Theravance Biopharma, Inc.
  • Tolero Pharmaceuticals, Inc.
  • Tragara Pharmaceuticals, Inc.
  • Vectura Group Plc

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1133TDB

Summary

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) pipeline Target constitutes close to 27 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Tyrosine Protein Kinase JAK2 - Pipeline Review, H2 2017, outlays comprehensive information on the Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Janus kinase 2 is a non-receptor tyrosine kinase. It is involved in various processes such as cell growth, development, differentiation or histone modifications. It mediates essential signaling events in both innate and adaptive immunity. It plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone, prolactin, leptin, erythropoietin, thrombopoietin or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. It plays a role in cell cycle by phosphorylating CDKN1B. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 3, 4, 6 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Gastrointestinal, Respiratory, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Hematological Disorders, Metabolic Disorders, Musculoskeletal Disorders and Ophthalmology which include indications Myelofibrosis, Myeloproliferative Disorders, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Atopic Dermatitis, Alopecia, Asthma, Auto Inflammatory Disease, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Glioblastoma Multiforme (GBM), Hematological Tumor, Leukemias, Myelodysplastic Syndrome, Polycythemia Vera, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Solid Tumor, Ulcerative Colitis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Astrocytoma, Autoimmune Disorders, B-Cell Leukemia, Cancer Anorexia-Cachexia Syndrome, Chronic Lymphocytic Leukemia (CLL), Dermatitis, Dermatomyositis, Diffuse Large B-Cell Lymphoma, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Essential Thrombocythemia, Giant Cell Arteritis, Gliosarcoma, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hypopharyngeal Cancer, Laryngeal Cancer, Lymphoma, Metastatic Prostate Cancer, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Parkinson's Disease, Peripheral T-Cell Lymphomas (PTCL), Proliferative Diabetic Retinopathy (PDR), Psoriatic Arthritis, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Failure, Respiratory Tract Inflammatory Disorders, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Thalassemia, Thrombocythemia Myelofibrosis, Vitiligo and Wet (Neovascular / Exudative) Macular Degeneration.

Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents 2
  • List of Tables 5
  • List of Figures 6
  • Introduction 7
  • Global Markets Direct Report Coverage 7
  • Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Overview 8
  • Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics Development 9
  • Products under Development by Stage of Development 9
  • Products under Development by Therapy Area 10
  • Products under Development by Indication 11
  • Products under Development by Companies 15
  • Products under Development by Universities/Institutes 21
  • Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics Assessment 23
  • Assessment by Mechanism of Action 23
  • Assessment by Route of Administration 24
  • Assessment by Molecule Type 26
  • Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Companies Involved in Therapeutics Development 27
  • Aerie Pharmaceuticals Inc 27
  • Aptose Biosciences Inc 27
  • AstraZeneca Plc 27
  • Bristol-Myers Squibb Co 28
  • Celon Pharma SA 28
  • Concert Pharmaceuticals Inc 29
  • CTI BioPharma Corp 29
  • Eli Lilly and Co 30
  • Genentech Inc 31
  • Incyte Corp 31
  • Japan Tobacco Inc 32
  • Nerviano Medical Sciences Srl 33
  • Novartis AG 33
  • NS Pharma Inc 34
  • Simcere Pharmaceutical Group 34
  • Theravance Biopharma Inc 35
  • Vectura Group Plc 35
  • Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Drug Profiles 37
  • APL-581 - Drug Profile 37
  • Product Description 37
  • Mechanism Of Action 37
  • R&D Progress 37
  • AR-13154 - Drug Profile 38
  • Product Description 38
  • Mechanism Of Action 38
  • R&D Progress 38
  • AZD-1480 - Drug Profile 39
  • Product Description 39
  • Mechanism Of Action 39
  • R&D Progress 39
  • baricitinib - Drug Profile 41
  • Product Description 41
  • Mechanism Of Action 41
  • R&D Progress 41
  • BVB-808 - Drug Profile 53
  • Product Description 53
  • Mechanism Of Action 53
  • R&D Progress 53
  • CHZ-868 - Drug Profile 54
  • Product Description 54
  • Mechanism Of Action 54
  • R&D Progress 54
  • CPL-407105 - Drug Profile 55
  • Product Description 55
  • Mechanism Of Action 55
  • R&D Progress 55
  • CTP-543 - Drug Profile 56
  • Product Description 56
  • Mechanism Of Action 56
  • R&D Progress 56
  • fedratinib - Drug Profile 59
  • Product Description 59
  • Mechanism Of Action 59
  • R&D Progress 59
  • jaktinib - Drug Profile 62
  • Product Description 62
  • Mechanism Of Action 62
  • R&D Progress 62
  • JTE-052 - Drug Profile 63
  • Product Description 63
  • Mechanism Of Action 63
  • R&D Progress 63
  • MA-2014 - Drug Profile 65
  • Product Description 65
  • Mechanism Of Action 65
  • R&D Progress 65
  • NMSP-113 - Drug Profile 66
  • Product Description 66
  • Mechanism Of Action 66
  • R&D Progress 66
  • NMSP-953 - Drug Profile 67
  • Product Description 67
  • Mechanism Of Action 67
  • R&D Progress 67
  • NS-018 - Drug Profile 68
  • Product Description 68
  • Mechanism Of Action 68
  • R&D Progress 68
  • pacritinib - Drug Profile 70
  • Product Description 70
  • Mechanism Of Action 70
  • R&D Progress 70
  • ruxolitinib phosphate - Drug Profile 84
  • Product Description 84
  • Mechanism Of Action 84
  • R&D Progress 84
  • SAR-317461 - Drug Profile 100
  • Product Description 100
  • Mechanism Of Action 100
  • R&D Progress 100
  • Small Molecule to Inhibit JAK2 for Leukemia - Drug Profile 101
  • Product Description 101
  • Mechanism Of Action 101
  • R&D Progress 101
  • Small Molecules to Inhibit JAK2 and JAK3 for Oncology and Auto Immune Disease - Drug Profile 102
  • Product Description 102
  • Mechanism Of Action 102
  • R&D Progress 102
  • Small Molecules to Inhibit JAK2 for Cancer - Drug Profile 103
  • Product Description 103
  • Mechanism Of Action 103
  • R&D Progress 103
  • Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders - Drug Profile 104
  • Product Description 104
  • Mechanism Of Action 104
  • R&D Progress 104
  • Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders - Drug Profile 105
  • Product Description 105
  • Mechanism Of Action 105
  • R&D Progress 105
  • TD-1473 - Drug Profile 106
  • Product Description 106
  • Mechanism Of Action 106
  • R&D Progress 106
  • TD-3504 - Drug Profile 108
  • Product Description 108
  • Mechanism Of Action 108
  • R&D Progress 108
  • TG-02 - Drug Profile 109
  • Product Description 109
  • Mechanism Of Action 109
  • R&D Progress 109
  • VR-588 - Drug Profile 112
  • Product Description 112
  • Mechanism Of Action 112
  • R&D Progress 112
  • Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Dormant Products 113
  • Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Discontinued Products 117
  • Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Product Development Milestones 119
  • Featured News & Press Releases 119
  • Oct 30, 2017: Lilly to Present New Data on its Anti-inflammatory Drug Candidate Baricitinib at ACR/ARHP Annual Meeting 119
  • Oct 19, 2017: Concert Pharmaceuticals Announces PTAB Denies Incyte Petition Challenging CTP-543 Patent 123
  • Sep 14, 2017: Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis 123
  • Sep 11, 2017: Lilly to Present New Data for Olumiant (baricitinib) at the European Academy of Dermatology and Venereology (EADV) Annual Congress 124
  • Sep 11, 2017: Olumiant is accepted for restricted use within NHS Scotland 124
  • Aug 30, 2017: Lilly To File Baricitinib Resubmission To U.S. FDA Before End Of January 2018 125
  • Aug 08, 2017: Theravance Biopharma Reports Encouraging Data from First Cohort of Patients in Phase 1b Clinical Trial of TD-1473 in Ulcerative Colitis 125
  • Aug 01, 2017: CTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with Myelofibrosis who have Thrombocytopenia and who have been Previously Treated with Ruxolitinib 127
  • Jul 25, 2017: Lilly And Incyte Provide Update On Baricitinib 127
  • Jul 13, 2017: CTI BioPharma Announces European Medicines Agency Validation of Pacritinib Marketing Authorization Application for Patients with Myelofibrosis who have Thrombocytopenia 128
  • Jul 10, 2017: FDA Lifts Clinical Hold on Concert Pharmaceuticals Clinical Trial with CTP-543 128
  • Jul 03, 2017: Japan Ministry Of Health, Labor And Welfare (MHLW) Grants Marketing Approval For Olumiant (Baricitinib) For The Treatment Of Rheumatoid Arthritis 129
  • Jun 29, 2017: NICE Recommends Lilly's Baricitinib (Olumiant) for the Treatment of Severe Rheumatoid Arthritis 129
  • Jun 16, 2017: New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017 130
  • Jun 13, 2017: Lilly To Present New Data On Olumiant (Baricitinib) In Rheumatoid Arthritis At The Annual European Congress Of Rheumatology (EULAR 2017) 131
  • Appendix 134
  • Methodology 134
  • Coverage 134
  • Secondary Research 134
  • Primary Research 134
  • Expert Panel Validation 134
  • Contact Us 134
  • Disclaimer 135

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017 9
  • Number of Products under Development by Therapy Areas, H2 2017 10
  • Number of Products under Development by Indications, H2 2017 11
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 13
  • Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 14
  • Number of Products under Development by Companies, H2 2017 15
  • Products under Development by Companies, H2 2017 16
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017 17
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017 18
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017 19
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017 20
  • Number of Products under Investigation by Universities/Institutes, H2 2017 21
  • Products under Investigation by Universities/Institutes, H2 2017 22
  • Number of Products by Stage and Mechanism of Actions, H2 2017 23
  • Number of Products by Stage and Route of Administration, H2 2017 25
  • Number of Products by Stage and Molecule Type, H2 2017 26
  • Pipeline by Aerie Pharmaceuticals Inc, H2 2017 27
  • Pipeline by Aptose Biosciences Inc, H2 2017 27
  • Pipeline by AstraZeneca Plc, H2 2017 28
  • Pipeline by Bristol-Myers Squibb Co, H2 2017 28
  • Pipeline by Celon Pharma SA, H2 2017 29
  • Pipeline by Concert Pharmaceuticals Inc, H2 2017 29
  • Pipeline by CTI BioPharma Corp, H2 2017 30
  • Pipeline by Eli Lilly and Co, H2 2017 30
  • Pipeline by Genentech Inc, H2 2017 31
  • Pipeline by Incyte Corp, H2 2017 32
  • Pipeline by Japan Tobacco Inc, H2 2017 33
  • Pipeline by Nerviano Medical Sciences Srl, H2 2017 33
  • Pipeline by Novartis AG, H2 2017 34
  • Pipeline by NS Pharma Inc, H2 2017 34
  • Pipeline by Simcere Pharmaceutical Group, H2 2017 35
  • Pipeline by Theravance Biopharma Inc, H2 2017 35
  • Pipeline by Vectura Group Plc, H2 2017 36
  • Dormant Products, H2 2017 113
  • Dormant Products, H2 2017 (Contd..1), H2 2017 114
  • Dormant Products, H2 2017 (Contd..2), H2 2017 115
  • Dormant Products, H2 2017 (Contd..3), H2 2017 116
  • Discontinued Products, H2 2017 117
  • Discontinued Products, H2 2017 (Contd..1), H2 2017 118

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017 9
  • Number of Products under Development by Therapy Areas, H2 2017 10
  • Number of Products under Development by Top 10 Indications, H2 2017 11
  • Number of Products by Stage and Mechanism of Actions, H2 2017 23
  • Number of Products by Routes of Administration, H2 2017 24
  • Number of Products by Stage and Routes of Administration, H2 2017 24
  • Number of Products by Stage and Molecule Type, H2 2017 26
Back to Top